• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.08% Nasdaq Up0.22%

    Enanta Pharmaceuticals, Inc. (ENTA)

    31.96 Down 0.04(0.13%) Nov 27, 1:00PM EST
    ProfileGet Profile for:
    Enanta Pharmaceuticals, Inc.
    500 Arsenal Street
    Watertown, MA 02472
    United States - Map
    Phone: 617-607-0800
    Fax: 617-607-0530
    Website: http://www.enanta.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products focuses on mechanisms gram-positive pathogens, including bacteria resistant and marketed macrolides. It has collaboration agreements with AbbVie Inc., Novartis, and National Institute of Allergy and Infectious Diseases. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Enanta Pharmaceuticals, Inc.

    Corporate Governance 
    Enanta Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 8. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Jay R. Luly Ph.D., 59
    Chief Exec. Officer, Pres and Director
    Mr. Paul J. Mellett Jr., 60
    Chief Financial Officer and Sr. VP of Fin. & Admin.
    Dr. Yat Sun Or Ph.D., 63
    Chief Scientific Officer and Sr. VP of R&D
    Mr. Nathaniel S. Gardiner J.D., 61
    Sr. VP, Gen. Counsel and Sec.
    Dr. Timothy D. Ocain Ph.D., 57
    Sr. VP of New Product Strategy and Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders